Teva agrees to buy Allergan unit for $40.5 billion, creating generics giant

On Monday, Teva, the world's top generic drug company, agreed to buy its No. 3 rival, Allergan Generics, for $40.5 billion in cash and stock. Teva, based in Israel, said both companies' boards have unanimously approved the deal for U.S.-based Allergan's generic drug unit. The merger is expected to close in the first quarter of 2016. In announcing the Allergan deal, Teva said that it has dropped its $40 billion bid for Mylan, its No. 4 global competitor.
If completed, the acquisition will not just increase Teva's share of the generics market — already 12 percent, according to The Wall Street Journal; it will also give the Israeli drugmaker greater annual revenue than many better-known name-brand pharmaceutical companies.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Why Jannik Sinner's ban has divided the tennis world
In the Spotlight The timing of the suspension handed down to the world's best male tennis player has been met with scepticism
By The Week UK Published
-
Crossword: February 22, 2025
The Week's daily crossword puzzle
By The Week Staff Published
-
Sudoku hard: February 22, 2025
The Week's daily hard sudoku puzzle
By The Week Staff Published
-
Trump's China tariffs start after Canada, Mexico pauses
Speed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
By Peter Weber, The Week US Published
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
By Peter Weber, The Week US Published
-
Getty Images and Shutterstock merge into a picture powerhouse to combat AI
The Explainer The $3.7 billion deal is one of the largest in the industry's history
By Justin Klawans, The Week US Published
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US Published
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US Published
-
Judges block $25B Kroger-Albertsons merger
Speed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
By Peter Weber, The Week US Published
-
Rupert Murdoch loses 'Succession' court battle
Speed Read Murdoch wanted to give full control of his empire to son Lachlan, ensuring Fox News' right-wing editorial slant
By Peter Weber, The Week US Published
-
Bitcoin surges above $100k in post-election rally
Speed Read Investors are betting that the incoming Trump administration will embrace crypto
By Peter Weber, The Week US Published